March 30, 2011 (Toronto, Ontario) — Caregivers using a transdermal patch to administer cholinesterase inhibitor (ChEI)–based therapy in individuals with Alzheimer's disease (AD) report greater overall ...

Novartis Corporation's Exelon Patch Receives First Worldwide Approval in US EAST HANOVER, N.J., July 9 -- Exelon Patch (rivastigmine transdermal system) has received its first worldwide approval in ...

According to the World Health Organization (WHO), an estimated 50 million people are living with dementia globally. This number is projected to increase to 82 million by 2030 and over 150 million by ...

Rivastigmine is a drug that may help people with Alzheimer’s disease improve thinking, memory, communication, and how they perform activities. It is a daily patch people wear on the skin. Alzheimer‘s ...

China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rivastigmine transdermal patch to treat mild to moderate Alzheimer’s disease. Developed by Sino Biopharm, ...

Please provide your email address to receive an email when new articles are posted on . A study of more than 1,000 patients with Parkinson’s disease dementia found that patients who also had ...

Breckenridge has received the Food and Drug Administration’s green light for rivastigmine transdermal system in dosage strengths of 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours. The product is ...

PINE BROOK, N.J.--(BUSINESS WIRE)--Today, Alvogen has launched the first generic equivalent of Exelon® patch (rivastigmine transdermal system) in the United States. The product will be marketed by ...

Luye Pharma Group today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México, S.A. de C.V and Exeltis Pharmaceuticals Holding, S.L (Exeltis), ...

ZURICH, Sept 24 (Reuters) - The European Union has approved Novartis's Exelon skin patch to treat Alzheimer's disease, the Swiss drugmaker said on Monday. "The European Commission has approved Exelon ...

Close Brothers and Santander do not intend to challenge the UK financial regulator's 9.1 billion pound ($12.31 billion) ‌compensation scheme for consumers who were allegedly mis-sold car finance, the ...